rs150230450
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM3_SupportingPP3BS1_Supporting
This summary comes from the ClinGen Evidence Repository: The c.6233C>G (p.Pro2078Arg) variant in USH2A was present in 0.4% (lower bound of the 95% CI of 50/10070) of Ashkenazi Jewish alleles in gnomAD v4. However, the next highest population frequency (aside from in the "remaining" group in gnomAD) was 0.002458% (29/1179812) of non-Finnish European alleles in gnomAD v4. Because this variant is likely a founder population in the AJ population, BS1 was downgraded to BS1_Supporting. The p.Pro2078Arg variant was detected in one proband with retinitis pigmentosa and the pathogenic variant in USH2A c.12067-2A>G but phase unknown (PM3_Supporting; Hadassah-Hebrew University Medical Center internal data, ClinVar SCV001161352.1, PMID:31456290). It has also been seen in at least 8 probands without a second variant identified in USH2A (Laboratory for Molecular Medicine, Invitae internal data, GeneDx, ClinVar SCV000201902.5, SCV001068267.2, SCV005078111.1). The REVEL computational prediction tool produced a score of 0.702, which is above the threshold necessary to apply PP3. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1_Supporting, PM3_Supporting, PP3 (ClinGen Hearing Loss VCEP specifications version 2; 1.15.2025). LINK:https://erepo.genome.network/evrepo/ui/classification/CA179550/MONDO:0019501/005
Frequency
Consequence
NM_206933.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
USH2A | ENST00000307340.8 | c.6233C>G | p.Pro2078Arg | missense_variant | Exon 32 of 72 | 1 | NM_206933.4 | ENSP00000305941.3 | ||
USH2A | ENST00000674083.1 | c.6233C>G | p.Pro2078Arg | missense_variant | Exon 32 of 73 | ENSP00000501296.1 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152026Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000235 AC: 59AN: 251166Hom.: 0 AF XY: 0.000214 AC XY: 29AN XY: 135710
GnomAD4 exome AF: 0.000118 AC: 173AN: 1461624Hom.: 2 Cov.: 34 AF XY: 0.000109 AC XY: 79AN XY: 727124
GnomAD4 genome AF: 0.000145 AC: 22AN: 152026Hom.: 0 Cov.: 32 AF XY: 0.000135 AC XY: 10AN XY: 74248
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
- -
Reported in association with retinitis pigmentosa in published literature (PMID: 31456290); however, limited clinical and segregation information provided; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31456290) -
- -
Retinitis pigmentosa Pathogenic:1
- -
not specified Uncertain:1
The Pro2078Arg variant in USH2A has not been reported in individuals with hearin g loss, but has been identified in 0.02% (1/4406) of African American chromosome s by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSN P rs150230450). Computational analyses (biochemical amino acid properties, conse rvation, AlignGVGD, PolyPhen2, and SIFT) suggest that the Pro2078Arg variant may impact the protein, though this information is not predictive enough to determi ne pathogenicity. In summary, additional data is needed to determine the clinica l significance of this variant. -
Usher syndrome Uncertain:1
The c.6233C>G (p.Pro2078Arg) variant in USH2A was present in 0.4% (lower bound of the 95% CI of 50/10070) of Ashkenazi Jewish alleles in gnomAD v4. However, the next highest population frequency (aside from in the "remaining" group in gnomAD) was 0.002458% (29/1179812) of non-Finnish European alleles in gnomAD v4. Because this variant is likely a founder population in the AJ population, BS1 was downgraded to BS1_Supporting. The p.Pro2078Arg variant was detected in one proband with retinitis pigmentosa and the pathogenic variant in USH2A c.12067-2A>G but phase unknown (PM3_Supporting; Hadassah-Hebrew University Medical Center internal data, ClinVar SCV001161352.1, PMID:31456290). It has also been seen in at least 8 probands without a second variant identified in USH2A (Laboratory for Molecular Medicine, Invitae internal data, GeneDx, ClinVar SCV000201902.5, SCV001068267.2, SCV005078111.1). The REVEL computational prediction tool produced a score of 0.702, which is above the threshold necessary to apply PP3. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: BS1_Supporting, PM3_Supporting, PP3 (ClinGen Hearing Loss VCEP specifications version 2; 1.15.2025). -
Usher syndrome type 2A;C3151138:Retinitis pigmentosa 39 Uncertain:1
- -
Usher syndrome type 2A Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at